Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

Semaglutide offers a multifaceted approach to type 2 diabetes treatment, enhancing insulin release and reducing blood sugar ...

A new study published in the New England Journal of Medicine showed that once-weekly injectable semaglutide led to ...

The use of semaglutide, a glucagon-like peptide 1 receptor agonist (GLP-1 RA), is not associated with an increased risk for ...

Reports of “Ozempic parties” followed, and, as the drug’s popularity surged, supply became a drag in various countries.

MASH曾名为非酒精性脂肪性肝炎（NASH），是代谢功能障碍相关脂肪性肝病（MAFLD）的晚期形式。MASH是导致肝脏相关死亡的主要原因，对全球卫生系统造成日益加重的负担。此外，MASH患者，特别是那些具有更多代谢风险因素（高血压、合并2型糖尿病）的 ...

2024年9月，诺和诺德成功完成了STRIDE临床3b期试验。这是一项为期52周的试验，比较了1.0 ...

Results demonstrated the mean total medical costs per patient per year decreased significantly after patients began ...

Novo Nordisk’s CEO has alerted healthcare professionals about the growing risks associated with compounded semaglutide, a ...

Wegovy® is the only version of semaglutide that is FDA-approved for weight loss, while Ozempic® and other forms of the drug ...

智通财经获悉，远程医疗平台公司Hims & Hers Health (HIMS.US)首席执行官Andrew Dudum表示，该公司正准备在2025年推出 诺和诺德 (NVO.US)的旧版GLP-1减肥疗法liraglutide的非专利版本。liraglutide分别以Victoza和Saxenda的形式销售，用于治疗糖尿病和肥胖症。

Compounded semaglutide can be an affordable alternative to brand-name weight loss injections like Ozempic and Wegovy. But ...